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A  toxicological  evaluation  of  a novel  cooling  agent,  2-(4-methylphenoxy)-N-(1H-pyrazol-3-yl)-N-(2-
thienylmethyl)  acetamide  (S2227;  CAS  1374760-95-8),  was  completed  for  the  purpose  of  assessing  its
safety  for  use  in  food  and  beverage  applications.  S2227  undergoes  rapid  oxidative  metabolism  in  vitro,
and  in rat  and  dog  pharmacokinetic  studies  is  rapidly  converted  to  its component  carboxylic  acid  and  sec-
ondary amine.  S2227  was  not  found  to be mutagenic  or clastogenic  in  vitro,  and  did not induce  micronuclei
in polychromatic  erythrocytes  in vivo.  The  secondary  amine  hydrolysis  product,  N-(2-thienylmethyl)-1H-
pyrazol-3-amine  (M179),  was  also  evaluated  for genotoxicity.  In  subchronic  oral  toxicity  studies  in  rats,2227
EMA GRAS
ubchronic toxicological evaluation
enetic toxicological evaluation
the  no-observed-adverse-effect-level  (NOAEL)  for  S2227  was  100  mg/kg/day  (highest  dose tested)  when
administered  by oral  gavage  for  90 consecutive  days.  Furthermore,  S2227  demonstrated  a lack  of mater-
nal toxicity,  as well  as adverse  effects  on fetal  morphology  at the  highest  dose  tested,  providing  a NOAEL
of  1000  mg/kg/day  for both  maternal  toxicity  and  embryo/fetal  development  when  administered  orally
during  gestation  to pregnant  rats.
© 2015  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an open  access  article  under  the CC. Introduction
Menthol, a monocyclic terpene derived from mint oil, has been
sed in a wide variety of consumer products such as toothpaste,
outhwashes, chewing gum, and candy mints to elicit a cooling
ensation that is associated with freshness and cleanliness. The
ooling sensation elicited by menthol has been attributed to its
bility to activate a member of the transient receptor potential
TRP) ion channel family, TRPM8, which is also activated by cold
emperatures (<30 ◦C). Many synthetic derivatives of menthol have
een developed for use in oral care products that produce the same
Abbreviations: AUC, area under the curve; CL, plasma clearance; Cmax, peak
lasma concentration; CYP450, cytochrome P450; FDA, Food and Drug Admin-
stration; FEMA, Flavour and Extract Manufacturers Association of the United
tates; GMP, Good Manufacturing Practices; HPBL, human peripheral blood lym-
hocytes; JV, jugular vein; LC/MS, liquid chromatography with mass spectrometry;
C,  methylcellulose; mnPCE, micronucleated bone marrow polychromatic erythro-
ytes; NOAEL, no-observed-adverse-effect-level; NOEL, no-observed-effect-level;
ECD, Organization for Economic Cooperation and Development; PCE, polychro-
atic erythrocytes; PK, pharmacokinetics; PV, portal vein; RCG, Relative Cell
rowth; RMI, Relative Mitotic Index; t1/2, half-life; Tmax, time to reach Cmax; TE, total
rythrocytes; TK, toxicokinetics; TRPM8, transient receptor potential melastatin 8;
ss, volume of distribution at steady-state.
∗ Corresponding author. Fax: +1 858 404 0750.
E-mail address: amy.arthur@senomyx.com (A.J. Arthur).
ttp://dx.doi.org/10.1016/j.toxrep.2015.09.001
214-7500/© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access
c-nd/4.0/).BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
cooling sensation without the nasal and oral irritant effects seen
with higher concentrations of menthol due to its volatile nature
[2]. Most notable of these are the non-volatile p-menthane car-
boxamides originally developed by Wilkinson Sword, Ltd. in the
1970’s [31]. Several of these p-menthane carboxamides have been
evaluated for potential genotoxicity and in vivo toxicity in rodents
[7–9] and have been commercialized including the widely used
N-ethyl-p-menthane-3-carboxamide (WS-3, FEMA 3455). A subset
of these compounds, notably FEMA 4496 (EvercoolTM 180), FEMA
4549 (EvercoolTM 190), and FEMA 4681 (WS-12), are signiﬁcantly
more potent than menthol (>10-fold) and are known to produce a
long-lasting cooling sensation [1,13,14].
More recently, researchers at Senomyx, Inc. have reported
a series of novel phenoxyacetylamides, including 2-(4-
methylphenoxy)-N-(1H-pyrazol-3-yl)-N-(2-thienylmethyl)
acetamide (S2227, CAS 1374760-95-8), which are potent activators
of TRPM8 [29]. Like several of the aforementioned p-menthane
carboxamides, S2227 demonstrates potent, long-lasting cooling
effects in sensory testing in a variety of prototype product appli-
cations. The structure of S2227 along with representative analogs
from the p-menthane carboxamide series is shown in Fig. 1.
S2227 was reviewed by the Expert Panel of the Flavor and
Extract Manufacturers Association of the United States (FEMA) and
determined to be generally recognized as safe (GRAS) under condi-
tions of intended use as a ﬂavor ingredient [3,20,15] and therefore
 article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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Fig. 1. Structures of S2227 and cu
s available for use in human food in the United States as a “FEMA
RAS” ﬂavor ingredient. S2227 was assigned FEMA GRAS Number
809 in 2014 [3].
The purpose of this publication is to summarize the results
btained from in vitro metabolism and in vivo pharmacokinetic (PK)
tudies, general toxicology studies in rodents, developmental tox-
city studies, and genotoxicity studies conducted with S2227 and
ts secondary amine hydrolysis product N-(2-thienylmethyl)-1H-
yrazol-3-amine (M179). Additional supporting data obtained in
hese studies with S2227 and M179 is included in a Supplementary
ata section in the online publication.
. Materials and methods
The batch of S2227 used for the in vitro metabolism, in vivo PK,
n vitro and in vivo genotoxicity, 28-day range-ﬁnding, and range-
nding developmental toxicity studies (Batch ID no. 58705651,
urity 99.1%), was synthesized at Senomyx, San Diego, CA using the
rocedure described in US Patent Application No. 2013/0324557 A1
29]. The batch of S2227 used for the 90-day subchronic, and deﬁni-
ive developmental toxicity studies (Batch ID no. 10640134, Lot
o. GXS-2013-052-1, purity 99.3%) was synthesized at Firmenich,
eneva, Switzerland using a slight modiﬁcation of the same syn-
hetic method.
The batches of the M179 hydrochloride salt used for the in vitro
enotoxicity studies (Batch ID no. 58711139, purity >97%; Batch
D no. 59094944, purity >98%), were synthesized at Senomyx, San
iego, CA using the procedure described in US Patent Application
o. 2013/0324557 A1 [29]. Likewise, the M179 hemisulfate salt
sed for the in vivo genotoxicity studies (Batch ID no. 60063722,
urity >98%) was also prepared at Senomyx, San Diego, CA by an
nalogous method.
All genetic toxicology studies were conducted in compliance
ith the FDA Good Laboratory Practices (GLP) regulations 21CFR
art 58 [11] and OECD guidelines [26]. The experimental design
or these studies followed the OECD Guidelines for the testing
f chemicals - 471, 473, 474 and 489 [23–25]. The 28-day dose-
ange ﬁnding studies and 90-day toxicology studies in rats were
onducted in compliance with the United States Food and Drug
dministration (FDA) Guidelines [12] Toxicological Principles for
he Safety of Food Ingredients; the 90-day subchronic toxicol-
gy study was also conducted in compliance with the FDA Good
aboratory Practice (GLP) Regulations, 21CFR Part 58. The develop-
ental toxicity range-ﬁnder and deﬁnitive studies were conducted
n accordance with the OECD Guidelines for Testing of Chemi-
als Guideline 414, Prenatal Developmental Toxicity Study [27]
nd the United States FDA Redbook 2000: IV.C.9.b Guidelines forly marketed cooling compounds.
Developmental Toxicity Studies [10]; the deﬁnitive study was  also
conducted in compliance with the FDA GLP regulations 21CFR Part
58 and OECD guidelines [26].
The receptor panel proﬁling and preliminary CYP450 inhibition
assays were conducted at Ricerca Biosciences, Taipei, Taiwan; the
follow up CYP450 inhibition assays were carried out by Absorption
Systems, Exton, PA. The hERG channel inhibition assay was carried
out by Aviva Biosciences, San Diego, CA. The plasma stability, in vitro
microsomal metabolism, pharmacokinetic, and in vivo metabolism
studies on S2227 and M179 were conducted at Senomyx, San
Diego, CA. The in-life portion of the pharmacokinetic study in dogs
was conducted at Charles River Laboratories, Wilmington, MA.
The analytical methods used for the pharmacokinetic and in vivo
metabolism studies can be found in the Supplementary data section
published online.
The in vitro genotoxicity studies for S2227 were conducted at
Nucro-Technics, Scarborough, Ontario, Canada; the in vivo mouse
micronucleus study was  conducted at WIL  Research, Ashland, OH.
All genotoxicity studies for M179 (hydrochloride and hemisulfate
salts) were conducted at BioReliance Corporation, Rockville, MD.
The 28-day and 90-day subchronic toxicity studies for S2227 were
conducted at MPI  Research, Mattawan, WI.  The developmental tox-
icity study on S2227 was  conducted at WIL  Research, Ashland,
OH. A description of the study designs is included in the individ-
ual study sections below. Detailed data tables for the genotoxicity,
subchronic and developmental toxicity studies can be found in the
Supplementary Data section published online.
3. In vitro receptor and cytochrome P450 proﬁling of S2227
In vitro tests were conducted with S2227 to assess whether
the compound interacts with any enzymes or receptors that might
cause adverse or unexpected effects or affect drug metabolism. Pre-
liminary in vitro screening for potential off-target activity of S2227
included tests for cytochrome P450 (CYP450) inhibition, a receptor
lead proﬁling panel (67 receptor binding assays for GPCRs, ion chan-
nels, nuclear receptors, transporters), and an hERG inhibition assay.
The preliminary tests for CYP450 inhibition were performed using
recombinant human enzymes expressed in insect Sf9 cells using
spectroﬂuorimetric substrates [4,21]. All assays were performed at
a concentration of 10 M of S2227. No signiﬁcant responses (≥50%
inhibition or stimulation) were found in the lead proﬁling recep-
tor screen. S2227 also did not signiﬁcantly inhibit the hERG ion
channel current (<10%) in an in vitro hERG electrophysiology (patch
clamp) assay [30]. The results from the CYP450 inhibition studies
are summarized in Table 1.
D.S. Karanewsky et al. / Toxicology Reports 2 (2015) 1291–1309 1293
Table  1
Cytochrome P450 inhibition of S2227.
CYP Spectroﬂuorimetric assay, human recombinant enzymes, Sf9 cells LC–MS/MS assay in human liver microsomes
Probe substrate % Inhibition (10 M) Probe substrate % Inhibition (10 M)
1A2 3-Cyano-7-ethoxycoumarin 59% Phenacetin 41%
2C9  3-Cyano-7-ethoxycoumarin 39% Diclofenac 12%
2C19  3-Cyano-7-ethoxycoumarin 95% S-mephenytoin 89%
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(2D6  3-Cyano-7-ethoxycoumarin 1
3A4  7-Benzyloxy-4-(triﬂuoromethyl)-coumarin 8
As a follow up to the results obtained using spectroﬂuorimetic
ubstrates, S2227 was retested on the same panel of CYP enzymes
tilizing pooled human liver microsomes (Absorption Systems,
xton, PA) and CYP-speciﬁc substrates with detection of the CYP-
peciﬁc metabolites by LC-MS/MS [18,32]. In this more deﬁnitive
ssay format, 10 M of S2227 demonstrated signiﬁcant inhibition
YP2C19 and CYP3A4 (midazolam substrate) (see Table 1). In a
eparate study, S2227 was also evaluated for evidence of time-
ependent inhibition of CYP2C19 and CYP3A4 again using human
iver microsomes and CYP-speciﬁc substrates. In this assay format,
he IC50’s of S2227 on CYP2C19 (S-mephenytoin substrate) and
YP3A4 (midazolam substrate) were 1.3 M and 15 M,  respec-
ively. While no evidence of time-dependent CYP inhibition was
een on CYP2C19, there was a suggestion of time-dependent inhi-
ition on CYP3A4 as indicated by a signiﬁcant increase in inhibition
hen the microsomes were pre-incubated with S2227 in the pres-
nce of NADPH.
. Absorption, distribution, metabolism, excretion
The in vitro metabolism of S2227 was studied using rat, dog, rab-
it, Gottingen pig, and human liver microsomes. The ex-vivo plasma
tability of S2227 was evaluated in rat, dog, rabbit, monkey, Got-
ingen pig, and human plasma. The in vivo metabolism and PK of
2227 was studied in both rats and dogs. The PK of both S2227 and
ts secondary amine hydrolysis product M179 was  also determined
n mice.
.1. In vitro metabolism
The potential of S2227 to undergo oxidative metabolism was
nvestigated using Sprague-Dawley rat, dog, rabbit, Gottingen pig,
nd human liver microsomes in order to determine the similarity of
he metabolic proﬁle across species and to assess the suitability of
he rat as a species for toxicology studies. S2227 (10 M) was  incu-
ated with mixed gender, pooled liver microsomes (0.5 mg/mL)
rom human, rat, dog, and rabbit, or with pooled liver microsomes
rom male Gottingen pigs (XenoTech, Lenexa, KS) in the presence
f NADPH at 37 ◦C for 10, 20, or 60 min  prior to quenching the
amples with acetonitrile. Control samples included time zero and
0 min  incubates without NADPH. Buspirone and loperamide were
ested in parallel with S2227 to conﬁrm the functionality of the
icrosomes. Samples were centrifuged to separate the precipitated
icrosomes from the supernatant containing the parent compound
nd it metabolites. The supernatants were analysed on an Agilent
550 Accurate Mass Q-TOF LC/MS system in order to evaluate the
etabolism of S2227. Details of the experimental and analytical
ethods can be found in the Supplementary data section.
S2227 was more rapidly metabolized by rat and pig than
y the dog or human microsomes during the 60 min  incubation
eriod. At the end of the 60 min  incubation, roughly 7.67%, 3.15%,
.00%, and 0.89% of S2227 was remaining for the dog, human,
at, and pig, respectively. The amide bond hydrolysis product, N-
2-thienylmethyl)-1H-pyrazol-3-amine (M179), was observed inBufuralol 15%
Testosterone 35%
Midazolam 57%
microsomal incubations with and without NADPH (i.e.,  non-CYP450
dependent pathway). In the case of the rabbit microsomes, hydroly-
sis was rapid; less than 15% of S2227 remained at T = 0 min  (i.e.,  time
of NADPH addition). In all other species, greater than 98% of S2227
remained at T = 0 min. Since relatively little S2227 remained at the
time of NADPH addition in the rabbit microsomes, the metabolite
proﬁle in rabbit microsomes was  not included in this analysis. A
graph of the S2227 % remaining (100% for T = 0 min) verses time in
the microsomal incubations is shown in Fig. 2.
A total of 27 metabolites were observed across all species.
Because S2227 was metabolized at different rates across species,
metabolite proﬁles in human, rat, dog, and pig microsomes were
compared at a time-point where 3.15–9.01% of S2227 remained.
The relative extracted ion chromatogram (EIC) peak areas (%) com-
pared to the S2227 peak area at T = 0 min  for the major metabolites
(relative peak area >1% for at least one species) of S2227 is shown
in Table 2 (positive ionization mode only). The structures assigned
to the major metabolites are shown in Fig. 3. The structures of
M179, M231, and M343A were conﬁrmed by direct comparison
to synthesized materials. The remaining structures are based on
exact masses and mass spectral fragmentation patterns and should
be considered tentative. The mass spectral fragmentation path-
way for the parent compound S2227 is shown in Fig. 4. The ions
corresponding to m/z 244.1081, 220.0539, and 97.0103 were the
major fragments seen in the electrospray ionization (ESI) prod-
uct ion spectra of S2227 and served as diagnostic fragments for
determining the position of the oxidative modiﬁcation of the parent
structure in the microsomal metabolites. For example, metabolites
in which the thiophene ring has been oxidized (e.g., M341A, M343D,
M359E, M361) lack the signal for the thienylmethyl cation (m/z
97.0103). Likewise, while this fragment ion is seen in the spectra of
metabolites M343B/C, the fragment corresponding to m/z  244.1081
now appears at m/z 260.1030 indicating that the pyrazole moiety
has undergone an oxidative modiﬁcation. Other fragment ions seen
in the mass spectra of these metabolites demonstrate that the (4-
methylphenoxy) acetic acid moiety remains intact and lend further
support to the proposed positions of oxidative metabolism.
The amide bond hydrolysis product M179 was produced by all
species in greater amounts than in human microsomes. The major
Phase I metabolites produced in human microsomes result from the
oxidative cleavage of the thienylmethyl group (M231), hydroxyla-
tion of the 4-methylphenoxy moiety (M343A), and from oxidation
of the thiophene ring (M343D and M361). The metabolite proﬁle in
dog microsomes was nearly identical to that of the human micro-
somes. The rat microsomes did not produce signiﬁcant quantities of
the M361 metabolite, and also produced large amounts of a M341A
(a further oxidation product of M343D) which is produced only in
trace quantities in human microsomes.
4.2. Ex-vivo plasma stability of S2227 in human, rat, dog, rabbit,
monkey, and Gottingen pig plasma
The relative stability of S2227 in human plasma as compared
to other species was  investigated in order to assess the suitabil-
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Fig. 2. Rate of metabolism of S2227 by rat, pig, dog and human liver microsomes.
Table 2
Major metabolites of S2227 in rat, dog, pig, and human microsomal incubations.
Metabolite m/z  (M + H) Formula Rat (20 min) Pig (10 min) Dog (60 min) Human (60 min)
S2227 328.1114 C17H18N3O2S+ 4.83 9.01 7.67 3.15
M179  180.0590 C8H10N3S+ 6.47 37.29 10.26 0.91
M231  232.1081 C12H14N3O2+ 1.89 3.68 5.14 8.68
M341A  342.0907 C17H16N3O3S+ 2.65 0.40 0.41 0.78
M343A  344.1063 C17H18N3O3S+ 16.78 7.92 13.67 6.31
M343B  344.1063 C17H18N3O3S+ 0.17 0.75 1.48 0.92
M343C  344.1063 C17H18N3O3S+ 1.91 0.21 0.43 0.26
M343D  344.1063 C17H18N3O3S+ 5.00 3.52 3.75 4.00
M359E  360.1013 C17H18N3O4S+ 0.48 2.64 0.19 0.78
M361  362.1169 C H N O S+ 0.42 0.78 1.99 2.52
N 0 min.
r
i
w
g
2
a
n
p
a
a
S
i
o
S
r
b
r
i
t
4
a
w
i
d
m17 20 3 4
umbers represent relative EIC peak areas (%) compared to S2227 peak area at T = 
esponse factors for all metabolites and S2227 are equivalent.
ty of the rat as a species for toxicology studies. S2227 (750 ng/mL)
as incubated with human, rat, dog, rabbit, monkey, or Gottin-
en pig plasma (Bioreclamation LLC, Westbury, NY) at 37 ◦C for
4 h. Aliquots (50 L) were taken at 0, 0.25, 0.5, 1.0, 2.0, 4.0, 6.0,
nd 24 h and diluted into acetonitrile (150 L) containing an inter-
al standard (IS). The samples were centrifuged to separate the
recipitated proteins from the supernatant. The supernatant was
nalysed by LC–MS/MS using an API 3200 QTrap equipped with
n Agilent 1100HPLC system in order to determine the percent of
2227 remaining at the various time points. All data were normal-
zed by ratio of peak area (S2227/IS) at the 0 h time point. Details
f the experimental and analytical methods can be found in the
upplementary data section.
S2227 was rapidly hydrolyzed in rat plasma with only 3.8%
emaining at the 15 min  time point. In contrast, S2227 was very sta-
le in human, dog, and pig plasma with 90.0%, 110.4%, and 91.7%,
espectively, remaining at the 24 h time point. S2227 was  less stable
n either monkey or rabbit plasma with 36.7% and 20.1%, respec-
ively, remaining at the 24-h time point (see Fig. 5).
.3. Pharmacokinetics and in vivo metabolism of S2227 in rats
nd dogs
The PK parameters and oral bioavailability of S2227 in plasma
as evaluated following either a single intravenous or oral admin-
stration in male/female Sprague-Dawley rats and male beagle
ogs. Plasma samples were also analyzed for the presence of the
etabolites observed in incubations of S2227 with rat and dog All statements of scale (quantitative) assume that the relative mass spectrometry
liver microsomes. For intravenous administration, 4 male and 4
female Sprague-Dawley [Crl:CD®(SD)] rats (Charles River Laborato-
ries, Hollister, CA), or 2 male dogs were bolus injected with S2227 at
1 mg/kg in PEG 400. Blood samples were collected at approximately
0, 2, 5, 10, 30 min, 1, 2, 4, and 8 h post-dose. For oral administra-
tion, 4 male and 4 female Sprague-Dawley rats, or 3 male dogs per
group were administered S2227 at either 10, 30, or 100 mg/kg in 1%
methylcellulose by oral gavage (rats) or in gelatin capsule (dogs).
Blood samples were taken at approximately 0, 15, 30 min, 1, 2, 4,
8, and 24 h post-dose. Plasma samples were analyzed for S2227
and metabolites by LC–MS/MS using an Agilent 6550 iFunnel Q-
TOF equipped with a 1290 UHPLC system. Details of the analytical
methods can be found in the Supplementary data section. Samples
analyzed by mass spectrometry (API 3200 QTRAP) included internal
standards for the parent compound S2227, as well as the car-
boxylic acid (M166) and secondary amine (M179) that result from
hydrolysis of the amide bond. The PK parameters were analysed by
non-compartmental methods using Phoenix WinNonlin software
(Pharsight, A Certara Company, Princeton, NJ). Plasma samples from
rats and dogs dosed orally at 100 mg/kg were analysed by Q-TOF
for the presence of the metabolites that were observed in the rat
and dog in vitro microsomal incubations. Test article formulations
prepared for this study were analysed for concentration before and
after dosing by HPLC-UV.
S2227 was rapidly eliminated after intravenous administra-
tion in both rats (t1/2 = 0.25-0.30 h) and dogs (t1/2 = 0.56 h) (see
Table 3 and Fig. 6). Mean plasma clearance (CL) in rats averaged
79.0 mL/min/kg for males (144% of hepatic blood ﬂow, [5] and
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Fig. 3. Tentative structures of S2227 major microsomal metabolites.
Table 3
Pharmacokinetics of S2227 in male/female S-D rats and male beagle dogs.
Route Dose (mg/kg) Species (sex) Cmax (ng/mL) Tmax (h) t1/2 (h) AUC0-last (ng·h/mL) AUC0-last/dose (ng·h/mL/mg/kg) %F
iv 1.0 Rat (M)  900 ± 196 0.03 0.25 222 ± 65.8 222 –
Rat  (F) 1332 ± 431 0.03 0.30 299 ± 59.6 299 –
Dog  (M)  1329 ± 94.0 0.13 0.56 942 ± 274 942 –
oral  gavage 10 Rat (M)  2.62 ± 0.33 0.75 0.60 1.64 ± 0.98 0.164 0.07%
Rat  (F) 8.51 ± 3.60 0.25 1.46 7.86 ± 3.60 0.786 0.26%
Dog  (M)  33.7 ± 27.5 1.50 1.92 119 ± 102 11.9 1.26%
30 Rat (M)  6.22 ± 4.58 0.31 0.89 6.22 ± 3.93 0.208 0.09%
Rat  (F) 33.1 ± 32.7 0.31 2.15 29.1 ± 16.0 0.971 0.32%
Dog  (M)  41.9 ± 25.5 1.67 4.47 223 ± 29.8 7.42 0.79%
100 Rat (M)  18.7 ± 4.58 1.00 3.02 50.1 ± 6.22 0.501 0.23%
Rat  (F) 47.8 ± 26.9 0.50 2.91 157 ± 71.5 1.57 0.53%
Dog  (M)  121 ± 29.5 1.67 5.25 704 ± 404 7.04 0.75%
M g; Vs
V
5
v
2
a
5
d
c
i
a
tale rat: CL = 79.0 mL/min/kg; Vss = 1810 mL/kg; Female rat: CL = 56.4 mL/min/k
ss = steady-state volume of distribution; %F = bioavailability.
6.4 mL/min/kg for females (103% of hepatic blood ﬂow), and the
olume of distribution at steady-state (Vss) averaged 1810 and
440 mL/kg for males and females, respectively. In dogs, CL aver-
ged 18.4 mL/min/kg (59% of hepatic blood ﬂow) and Vss averaged
93 mL/kg. Despite the signiﬁcantly greater stability of S2227 in
og vs rat plasma ex-vivo, S2227 was rapidly converted to its
omponent carboxylic acid M166 and secondary amine M179 on
ntravenous administration in both rat and dog (see Tables 4 and 5,
nd Figs. 6 and 7). After oral administration, systemic exposure
o S2227 was also relatively low in both species, but tended tos = 2440 mL/kg; Male dog: CL = 18.4 mL/min/kg; Vss = 593 mL/kg; CL = clearance;
be somewhat higher in dogs (see Table 3, Fig. 7). For example,
at 100 mg/kg, the mean Cmax for the male rats was  18.7 ng/mL
(0.057 M)  and 121 ng/mL (0.386 M)  in male dogs; the mean
AUClast was 50.1 ng·h/mL and 704 ng·h/mL in rats and dogs, respec-
tively (see Table 3). In contrast, systemic exposure to the acid M166
hydrolysis product was  signiﬁcantly greater in both species (see
Table 4). At the 100 mg/kg oral dose, the Cmax for acid M166 was
9619 ng/mL (57.9 M)  in male rats and 8342 ng/mL (50.2 M)  in
male dogs; AUClast was 47520 and 92580 ng·h/mL for male rats and
dogs, respectively. However, the amine hydrolysis product M179,
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ppears to be more rapidly excreted and/or metabolized in dogs
han in rats (see Table 5). At 100 mg/kg, the Cmax for amine M179
as 1011 ng/mL (5.64 M,  male rat) and 23.1 ng/mL (0.129 M,
ale dogs); AUClast was 3500 and 171 ng·h/mL for male rats and
ogs, respectively. The exposure (AUClast) to S2227 and its hydrol-
sis products M166 and M179 was somewhat higher in female rats
han in males, and increased in a dose proportional manner with
ncreasing oral dose. In dogs, exposure to S2227 and its hydrolysis
roducts also increased with increasing oral dose, but tended to be
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Fig. 5. Time course of S2227 plasma staentation pathway for S2227.
less than dose proportional. There was also evidence of enterohep-
atic recirculation of the carboxylic acid hydrolysis product M166 in
the dog. For example, the mean plasma concentration of M166 in
dogs at the 100 mg/kg oral dose was  7130 ng/mL (42.9 M)  at the
24 h time point verses 1790 (10.8 M)  at the 8 h time point. This
phenomenon was  not observed in the rat.In addition to the carboxylic acid M166 and secondary amine
M179 amide bond hydrolysis products, seven Phase I and two
Phase II metabolites of S2227 were observed in the rat plasma
15 20 25
ours)
bility in various species at 37 ◦C.
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Fig. 6. Mean plasma concentrations of S2227, M166, and M179 after intravenous administration of S2227 (1.0 mg/kg) to male S-D rats and male beagle dogs.
Table 4
Pharmacokinetics of carboxylic acid metabolite M166 in male/female S-D rats and male beagle dogs.
Route Dose (mg/kg) Species (sex) Cmax (ng/mL) Tmax (h) t1/2 (h) AUC0-last (ng·h/mL) AUC0-last/dose (ng·h/mL/mg/kg) AUC0-last ratio M166/S2227
iv 1.0 Rat (M)  448 ± 25.1 0.33 0.86 554 ± 219 554 2.50
Rat  (F) 756 ± 184 0.33 1.01 1010 ± 501 1010 3.38
Dog  (M)  506 ± 159 1.50 4.17 2790 ± 1031 2790 2.96
oral  gavage 10 Rat (M)  2558 ± 1240 0.63 1.34 5710 ± 2120 571 3480
Rat  (F) 3470 ± 1120 0.63 1.23 7700 ± 1440 770 979
Dog  (M) 1507 ± 552 4.67 4.77 15130 ± 6170 1513 127
30 Rat  (M)  4843 ± 1680 1.38 1.91 14845 ± 3210 495 2380
Rat  (F) 9732 ± 4240 0.81 1.70 25920 ± 6260 864 890
Dog  (M)  1783 ± 471 9.33 4.42 25930 ± 5840 864 117
100 Rat  (M)  9619 ± 4650 1.50 3.29 47520 ± 19000 475.2 949
Rat  (F) 12304 ± 5360 2.00 2.85 74230 ± 30700 742.3 473
Dog  (M)  8342 ± 5560 17.3 6.07 92580 ± 62600 925.8 132
Table 5
Pharmacokinetics of secondary amine metabolite M179 in male/female S-D rats and male beagle dogs.
Route Dose (mg/kg) Species (sex) Cmax (ng/mL) Tmax (h) t1/2 (h) AUC0-last (ng·h/mL) AUC0-last/dose (ng·h/mL/mg/kg) AUC0-last ratio M179/S2227
iv 1.0 Rat (M) 15.1 ± 3.23 0.11 0.28 8.78 ± 1.97 8.78 0.040
Rat  (F) 14.0 ± 4.84 0.13 0.82 12.6 ± 5.02 12.6 0.042
Dog  (M)  5.20 ± 0.90 0.50 1.10 6.63 ± 0.90 6.63 0.007
oral  gavage 10 Rat (M) 189 ± 94.5 0.50 1.12 254 ± 102 25.4 155
Rat  (F) 407 ± 289 0.44 1.02 384 ± 267 38.4 48.9
Dog  (M)  10.2 ± 4.84 4.67 4.77 22.2 ± 8.78 2.22 0.187
30 Rat  (M) 290 ± 115 0.75 1.29 614 ± 201 20.5 98.6
Rat  (F) 1538 ± 1050 0.75 1.06 2511 ± 1700 83.7 86.2
Dog  (M)  6.81 ± 2.15 1.00 2.27 31.0 ± 15.4 1.03 0.139
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A100 Rat  (M) 1011 ± 367 1.13 1.83 
Rat  (F) 1774 ± 457 0.83 1.84 
Dog  (M)  23.1 ± 7.71 10.0 4.69 
amples. The Phase I metabolic biotransformation of S2227 in
he rat involved oxidative cleavage of the thienylmethyl group to
231, hydroxylation of the pyrazole moiety to M343B and M343C,
ydroxylation and oxidation of the 4-methylphenoxy moiety to the
orresponding alcohol M343A and carboxylic acid M357D, hydrol-
sis of M343A to the carboxylic acid/alcohol M182, and hydrolysis
f M357D to the dicarboxylic acid M196. Phase II metabolites
onsisted of the acyl glucuronide M533A derived from carboxylic
cid M357D and M519B derived from glucuronidation of M343C.
ased on EIC peak areas, metabolites M166, M179, M357D, M343C,
nd M533A were present at higher concentrations than the par-
nt compound S2227 throughout the entire 24 h collection period.
lcohol M343A appears to be rapidly converted to acid M357D,0 ± 813 35.0 69.9
0 ± 745 59.8 38.1
 ± 144 1.71 0.243
which in turn, is converted to acyl glucuronide M533A in the
rat.
With the exception of oxidative metabolites M343C, M182,
and dicarboxylic acid M196, the same Phase I metabolites were
also observed in dog plasma. In addition to the acyl glucuronide
metabolite M533A, a third Phase II metabolite M519A derived
from glucuronidation of alcohol M343A, was also observed in the
dog. Based on MS  peak areas, carboxylic acids M166 and M357D,
and glucuronides M519A and M533A, were the major metabolites
observed in dog and were present at higher concentrations than
the parent compound S2227 throughout the entire 24 h collec-
tion period. As was  observed in the case of the rat, alcohol M343A
appears to be a transient intermediate which is rapidly converted
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Fig. 7. Mean plasma concentrations of S2227, M166, and M179 after oral administration of S2227 (100 mg/kg) to male S-D rats and male beagle dogs.
Fig. 8. Metabolic Pathway of S2227 in Rat and Dog.
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Table  6
S2227 and its metabolites oberved in rat and dog plasma at 1 h post-dose (100 mg/kg, po).
Rat Dog
Metabolite m/z (positive) Formula Peak area % Peak area Peak area % Peak area
S2227 328.1114 C17H18N3O2S+ 11800 0.52 11400 10.45
M179  180.0590 C8H10N3S+ 1760000 78.05 7090 6.50
M231  232.1081 C12H14N3O2+ 7270 0.32 – –
M343B 344.1063 C17H18N3O3S+ – – 3560 3.26
M343C 344.1063 C17H18N3O3S+ 76000 3.37 – –
M357D 358.0856 C17H16N3O4S+ 369000 16.36 18900 17.33
M519A 520.1384 C23H26N3O9S+ – – 45100 41.36
M519B 520.1384 C23H26N3O9S+ 5230 0.23 – –
M533A 534.1177 C23H23N3O10S+ 25700 1.14 23000 21.09
Metabolite m/z (negative) Formula Peak area % Peak area Peak area % Peak area
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SM166 165.0557 C9H9O3 442
M182  181.0506 C9H9O4− 234
M196  195.0299 C9H7O5− 188
o metabolites M357D, M519A, and M533A in the dog. None of the
icrosomal metabolites involving oxidation of the thiophene ring
M341A, M343D, M359E, and M361) were seen in either the rat
r dog plasma samples at any time point. With the exception of
343B/C and M519B, the identities of the remaining nine of rat/dog
n vivo metabolites were conﬁrmed by direct comparison to syn-
hetic standards. The metabolic pathway for S2227 in rat and dog is
hown in Fig. 8. The plasma concentrations of S2227 and its metabo-
ites at the 1-h time point can be found in Table 6. The time course
ata for S2227 and its metabolites over the entire 24 h collection
eriod can be found in the Supplementary data section.
.4. Pharmacokinetics of S2227 and S179 in mice
The plasma concentrations of the secondary amine hydroly-
is product N-(2-thienylmethyl)-1H-pyrazol-3-amine (M179) were
etermined following oral administration of equimolar levels of
ither S2227 or M179 hydrochloride salt to male Crl:CD-1(ICR)
ice (Charles River Laboratories, Hollister, CA). Two  groups of 28
ale CD-1 mice/group were dosed by oral gavage with a sus-
ension of either S2227 (30 mg/kg) or M179 hydrochloride salt
20 mg/kg) in 1% methyl cellulose (MC). Blood samples were taken
t approximately 15, 30 min, 1, 2, 4, 8, and 24 h post dose from 4 ani-
als/group/ time point by cardiac puncture. Plasma samples from
nimals dosed with S2227 were analysed for S2227 and metabolites
179 and M166 (carboxylic acid hydrolysis product) using inter-
al standards by LC–MS/MS on an AB Sciex 3200 QTRAP system
quipped with an Agilent 1100 binary pump and a CTC PAL injec-
or. Plasma samples from animals dosed with M179 hydrochloride
alt were analyzed only for M179 utilizing the same system. The PK
arameters were analysed by non-compartmental methods using
hoenix WinNonlin software. Test article formulations prepared for
his study were analyzed for concentration before and after dosing
y HPLC-UV. Details of the experimental and analytical methods
an be found in the Supplementary data section.
As was observed previously in both rats and dogs, S2227 was
apidly hydrolysed to the corresponding carboxylic acid M166
nd secondary amine M179 after oral administration to mice.
s a result, the systemic exposure to the parent amide S2227
as very low; Cmax = 125 ng/mL (0.382 M),  AUClast = 128 ng·h/mL.
fter an oral dose of S2227, the exposure to the secondary amine
etabolite M179 was also very low; Cmax = 27.8 ng/mL (0.155 M):
UClast = 27.6 ng·h/mL. In contrast, exposure to the carboxylic acid
etabolite M166 was nearly 100-fold greater [Cmax = 11290 ng/mL
67.95 uM), AUClast = 61730 ng·h/mL] than either S2227 or M179.
hese data are consistent with results obtained in the PK study of
2227 in dogs, and differ from the results of the PK study in rats, 95.43 478000 100.00
0.51 – –
4.06 – –
in which much higher levels of amine M166 were seen after oral
administration of S2227.
M179 hydrochloride salt was  rapidly absorbed (Tmax = 0.25 h)
and rapidly eliminated (t1/2 = 0.46 h) on oral administration to
mice, but still resulted in much higher levels of M179 in plasma
[Cmax = 9790 ng/mL (54.62 M),  AUClast = 4370 ng·h/mL] than was
seen with an equimolar dose of S2227. Taken together, the data
suggest that the majority of the amide bond hydrolysis of S2227
occurs post-absorption and not within the intestinal lumen.
5. Genotoxicity and mutagenicity studies
Both S2227 and M179 were evaluated for their genotoxic poten-
tial through a standard (5-strain) Ames, chromosome aberration,
and micronucleus tests (see Table 7). An alkaline comet assay was
also conducted on the livers of the mice treated with M179. All
genetic toxicology studies were conducted in compliance with the
FDA GLP regulations 21CFR Part 58 (2006) and OECD guidelines
(1998). The data tables for the genotoxicity studies can be found in
the Supplemental material.
5.1. Bacterial reverse mutation test (5-strain Ames)
S2227 and M179 hydrochloride salt were evaluated for the
potential to induce point mutations in S. typhimurium strains TA98,
TA100, TA1535, TA1537 and E. coli strain WP2  uvrA (Molecular Tox-
icology Inc., Boone, NC) in the presence and absence of metabolic
activation with rat liver S9 from rats induced with AroclorTM 1254.
The assay was  designed to meet the current OECD Guideline for
Testing of Chemicals No. 471, Bacterial Reverse Mutation Test [23].
The concentrations of S2227 investigated for both the plate
incorporation and pre-incubation tests ranged from 63 to 1000 g
per plate. In the plate incorporation assay, toxicity was not observed
at any concentration evident by a normal background lawn and
colony counts similar to the concurrent negative controls; a slight
precipitate was  visible at 250 and 1000 g/plate. In the pre-
incubation assay, precipitate was  visible only at 1000 g/plate and
the colony counts for TA1537 without S9 were slightly reduced at
the highest concentration of 1000 g/plate. The background lawns
for TA1537 were also slightly reduced at the highest concentration
of 1000 g/plate with and without S9. Despite this apparent toxi-
city, all 5 concentrations were analyzable for mutagenicity. S2227
did not increase the number of revertant colonies in either the plate
incorporation or pre-incubation assays with any of the tester strains
both in the presence and absence of metabolic activation with rat
liver S9.
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Table 7
Summary of genotoxicity studies conducted on S2227 and M179.
End-Point Test system Cmpd No. Concentration/dose Result
Reverse mutation (in vitro) S. typhimurium strains TA98,
TA100, TA1535, TA1537 and E. coli
strain WP2  uvrA
S2227 63–1000 g/plate, plate incorporation
and pre-incubation, ±S9a
Negative
M179 50–5000 g/plate, initial and
conﬁrmatory plate incorporation, ±S9a
Negative
Chromosome aberration (in vitro) Primary human lymphocytes S2227 35–160 g/mL, 3 h exposure −S9,
1.3–5.0 g/mL, 3 h exposure +S9b,
23–65 g/mL, 20 h exposure −S9
Negative
M179 280–2160 g/mL, 4 h exposure −S9
100–1840 g/mL, 4 h exposure +S9a
25–280 g/mL, 20 h exposure −S9
Positive (4 h,−S9)
Micronucleus formation (in vivo) Male & female Swiss albino mice
(CD-1), bone marrow PCEs
S2227 Males and females: 500, 1000,
2000 mg/kg bw (oral)
Negative
M179 Males: 125, 250, 500 mg/kg bw (oral)
Females: 250, 500, 1000 mg/kg bw
(oral)
Negative
DNA  damage (in vivo) Male & female Swiss albino mice
(CD-1), liver Comet assay
M179 Males: 125, 250, 500 mg/kg bw (oral)
Females: 250, 500, 1000 mg/kg bw
(oral)
Negative
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b S9 from rat liver homogenate (9000 ×g fraction) from male Sprague-Dawley ra
The assay for M179 hydrochloride salt was conducted in
wo phases (initial toxicity-mutation and conﬁrmatory mutation
ssays), using the plate incorporation method at nominal concen-
rations ranging from 50 to 5000 g/plate. Neither precipitate nor
ackground lawn toxicity was observed in either test at M179 con-
entrations up to 5000 g/plate. M179 did not increase the number
f revertant colonies in either the initial toxicity-mutation or the
onﬁrmatory mutation assays with any of the tester strains both in
he presence and absence of metabolic activation with rat liver S9.
In all tests, the positive and vehicle controls yielded the expected
esults. Thus, it was concluded that both S2227 and M179 were not
utagenic to S. typhimurium strains TA98, TA100, TA1535, TA1537
nd E. coli strain, WP2  uvrA at concentrations up to 1000 g/plate
or S2227 and 5000 g/plate for M179, in the absence and presence
f metabolic activation.
.2. In vitro chromosome aberration test
S2227 and M179 hydrochloride salt were investigated for their
otential to induce structural and numerical chromosome aberra-
ions in mammalian cells, both in the presence and absence of a
upplemental rat liver fraction (S9). The experimental design fol-
owed the OECD guideline for the testing of chemicals No. 473,
n vitro mammalian chromosome aberration test [24]. For S2227, a
reliminary toxicity test was performed to establish the dose range
or testing in the cytogenetic test.
In the case of S2227, cultures of human peripheral blood lym-
hocytes (HPBL, StemCell Technologies, Vancouver, BC, Canada)
ere treated for 3 and 20 h in the non-activated test system, and
or 3 h in the presence of S9 from rats induced with phenobarbi-
al and 5,6-benzoﬂavone. Solvent and positive control (mitomycin
, -S9; cyclophosphamide, +S9) cultures were also included. Test
rticle precipitate was only observed in the test system for 3 h
xposure at a concentration of 260 g/mL. In the preliminary tox-
city assay, substantial toxicity (at least 50% reduction in mitotic
ndex relative to the vehicle control) was observed at 260 g/mL
n the non-activated 3-h exposure groups, at 5.0 g/mL in the S9-
ctivated 3-h exposure group, and at dose levels ≥110 g/mL in the
on-activated 20-h exposure group. Based on these ﬁndings, the
oses chosen for the chromosome aberration assay ranged from 35
o 160 g/mL for the non-activated 3-h exposure group, from 1.3
o 5.0 g/mL for the S9-activated 4-h exposure group, and from
3 to 65 g/mL for the non-activated 20-h exposure group. Allted with Aroclor-1254
ted with phenobarbital/5,6-benzoﬂavone
conditions were tested at the limit of test article toxicity evalu-
ated by relative cell growth (RCG) and relative mitotic index (RMI)
levels.
Under these test conditions, no structural or numerical chro-
mosome aberrations were observed in the S2227 treated cultures
beyond those seen in the concurrent solvent controls. All concur-
rent positive controls induced signiﬁcant numbers (p < 0.01) of cells
with chromosome aberrations. It was concluded that exposure to
S2227 did not induce chromosome aberrations in the in vitro mam-
malian chromosome aberration test using HPBL in both the absence
and presence of rat liver S9, when tested in accordance with regu-
latory guidelines.
In the case of M179 hydrochloride salt, cultures of HPBL from a
healthy, non-smoking adult female were treated for 4 and 20 h in
the non-activated test system, and for 4 h in the presence of S9 from
rats treated with treated with AroclorTM 1254. Solvent and posi-
tive control (mitomycin C, -S9; cyclophosphamide, +S9) cultures
were also included. In the preliminary toxicity assay, substantial
toxicity (at least 50% reduction in mitotic index relative to the vehi-
cle control) was  observed at 2160 g/mL in the non-activated and
S9-activated 4 h exposure groups, and at dose levels ≥216 g/mL
in the non-activated 20 h exposure group. Based on these ﬁnd-
ings, the doses chosen for the chromosome aberration assay ranged
from 280 to 2160 g/mL for the non-activated 4 h exposure group,
from 100 to 1840 g/mL for the S9-activated 4 h exposure group,
and from 25 to 280 g/mL for the non-activated 20 h exposure
group.
No signiﬁcant or dose-dependent increases in structural aberra-
tions were observed in the S9-activated 4 h and the non-activated
20 h exposure groups (p > 0.05). In the non-activated 4 h exposure
group, a statistically signiﬁcant and dose-dependent increase in
structural aberrations (5.5–6.0%, p ≤ 0.01) was observed at dose
levels 2000 and 2160 g/mL. No signiﬁcant or dose-dependent
increases in numerical aberrations were observed in any of the
treatment conditions (p > 0.05). All vehicle control values were
within historical ranges, and the positive controls induced signif-
icant increases in the percent of aberrant metaphases (p ≤ 0.01).
M179 was  concluded to be positive in the non-activated test sys-
tem, but negative in S9-activated test system, for the induction of
structural aberrations in the in vitro chromosome aberration assay
in HPBL. M179 was negative for the induction of numerical aberra-
tions in both the non-activated and S9-activated test systems under
the conditions of this assay.
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.3. In vivo micronucleus assay in mice
S2227 and M179 hemisulfate salt were evaluated for potential in
ivo clastogenic activity and/or disruption of the mitotic apparatus,
s measured by their ability to increase the incidence of micronu-
leated polychromatic erythrocytes (mnPCEs) in the bone marrow
f CD-1 mice. The study was designed to meet the current OECD
uideline for the Testing of Chemicals No. 474, Mammalian Ery-
hrocyte Micronucleus Test [25].
Dose-range ﬁnding studies were performed to assess test arti-
les toxicity and determine the maximum tolerated dose (MTD)
r maximum feasible dose (MFD) for the deﬁnitive assay. For both
he dose range ﬁnding and deﬁnitive phases of the study, male and
emale Crl:CD-1(ICR) mice (Charles River Laboratories, Portage, MI)
ere treated with S2227 suspended in vehicle (1% methylcellu-
ose (MC) in puriﬁed water) at a volume of 10 mL/kg body weight
or three consecutive days by oral gavage. In the deﬁnitive phase
f the study, 1% MC  was used as the vehicle (negative) control
nd cyclophosphamide monohydrate (CP), at a dose of 60 mg/kg,
as used as the positive control article. For the study with M179
emisulfate salt, male and female Hsd:ICR(CD-1) mice (Harlan Lab-
ratories, Frederick, MD)  were treated with M179 hemisulfate salt
uspended in 1% MC  at a volume of 20 mL/kg body weight for three
onsecutive days by oral gavage. In the deﬁnitive phase of the
tudy, 1% MC  was used as the vehicle (negative) control and methyl
ethanesufonate (MMS), at a dose of 40 mg/kg/day, was used as the
ositive control article. Animals were observed for signs of toxicity
uring the course of these studies.
In the preliminary dose range ﬁnding study with S2227, mice (3
nimals/sex/group) were dosed with S2227 at 500, 1000, 1500 and
000 mg/kg for three consecutive days. Since there was  no toxicity
oted up to 2000 mg/kg, dose levels of 500, 1000, and 2000 mg/kg (6
nimals/sex/group), were used for the deﬁnitive study with S2227.
n the dose ranging study with M179, mice (3 animals/sex/group)
eceived three consecutive daily doses of M179 hydrochloride salt
t 125, 250, 500, 1000 and 2000 mg/kg/day. Mortality occurred
uring the dose range ﬁnding assay in 3/3 males and 3/3 females
t 2000 mg/kg and 2/3 males at 1000 mg/kg/day. Clinical signs
ncluded piloerection observed at all dose levels; lethargy observed
t the 500 and 1000 mg/kg/day dose levels and prostration and
rregular breathing observed at the 1000 and 2000 mg/kg/day dose
evels. All other mice appeared normal throughout the observation
eriod. Due to the mortality and observations seen during the dose
ange ﬁnding assay, the dose levels of 125, 250, and 500 mg/kg in
ale mice, and 250, 500 and 1000 mg/kg in female mice, were used
or the deﬁnitive study with M179 (5 animals/sex/group).
In the deﬁnitive assay, all animals from each of the test arti-
le treated, vehicle, and positive control groups were euthanized
ither 18–24 h (S2227 study) or 3–4 h (M179 study) after the last
ose by CO2 inhalation. Immediately following euthanasia by car-
on dioxide inhalation, femoral bone marrow was collected from
ach animal. Bone marrow slides were prepared and polychromatic
rythrocytes (PCEs, 2000/animal) were examined microscopically
or the presence of micronuclei (mnPCEs). The ratio of PCEs to total
rythrocytes (TE) in the test article groups relative to the vehi-
le control groups was also evaluated to reﬂect the test article’s
ytotoxicity. In the case of the M179 treated animals, all animals
ere also dissected and the liver removed and collected for a liver
lkaline comet assay (vide infra).
All animals dosed with S2227 appeared normal throughout the
onduct of the study. There were no test article-related clinical
bservations or effects on body weights or food consumption. For
179, no mortality occurred at any dose level during the course
f the deﬁnitive assay; however, clinical signs included piloerec-
ion observed at all M179 dose levels; lethargy observed at 500
nd 1000 mg/kg/day; prostration, irregular breathing and crustyReports 2 (2015) 1291–1309 1301
eyes observed at 1000 mg/kg/day in female mice. All other mice
appeared normal throughout the observation period.
No appreciable reductions in the PCE/TE ratio in either the S2227
or M179 treated groups compared to the vehicle control group were
observed indicating that the test articles did not induce cytotoxic-
ity. No statistically signiﬁcant increase in the incidence of mnPCEs
in either the S2227 or M179 treated groups was observed rela-
tive to the negative control group. The positive controls (CP or
MMS)  induced statistically signiﬁcant increases in the incidence of
mnPCEs when compared to both the negative control groups and
the test article treated groups at all three dose levels. It was con-
cluded that oral administration of either S2227 or M179 at did not
induce micronuclei in male and female CD-1 mice when tested in
accordance with regulatory guidelines.
5.4. In vivo alkaline comet assay in mice
In conjunction with the in vivo micronucleus study of M179
hemisulfate salt described in Section 5.3, M179 was also assessed
for its potential to induce DNA damage in the liver cells by single
cell gel electrophoresis (i.e., the alkaline comet assay) in the same
animals evaluated for micronuclei induction in PCEs in bone mar-
row. The comet assay design was based on JaCVAM protocol version
14.2 [16] and is in accord with the recently adapted OECD Guideline
for the Testing of Chemicals No. 489, In Vivo Mammalian Alkaline
Comet Assay [28].
In the same animals assessed for micronuclei induction, M179
was negative (non-DNA damaging) in the liver based on the results
of the comet assays. There were no statistically signiﬁcant differ-
ences in the % tail DNA in the liver cells of the male and female
M179 treated mice (all three dose groups) and the vehicle control
mice. The number of “clouds” (aka “hedgehogs”) in the test arti-
cle dosed animals were similar to that the vehicle control. The %
tail DNA for the positive control (MMS)  was  signiﬁcantly (p < 0.05)
above that of the vehicle control. Based on the results of the comet
assay, it was concluded that M179 hemisulfate salt, at doses up to
and including 500 mg/kg/day in male mice and up to and includ-
ing 1000 mg/kg/day in female mice, was  non-DNA damaging to the
liver, under the conditions of this test.
6. In vivo toxicological studies
S2227 was  evaluated in 28-day dose-range ﬁnding and 90-day
toxicology studies in rats in compliance with the United States Food
and Drug Administration (FDA) Guidelines [12] Toxicological Prin-
ciples for the Safety of Food Ingredients. S2227 was also evaluated
for potential embryo/fetal toxicity in a gestational developmental
toxicity study in rats. The developmental toxicity study consisted
of two  phases, a range-ﬁnding study and a deﬁnitive study in which
the test animals were evaluated for both maternal toxicity and
effects on embryo/fetal development. Summary data tables for 90-
day toxicology and the deﬁnitive developmental toxicity studies
for S2227 can be found in the Supplemental material (see Table 8).
6.1. Subchronic toxicology studies
6.1.1. 28-Day dose-range ﬁnding toxicity study
The purpose of these studies was  to evaluate the potential sys-
temic toxicity of S2227 in rats after dietary administration for
28 days in order to select doses for 90-day subchronic toxic-
ity studies in rats. Three treatment groups of male and female
CD® [Crl:CD®(SD)] rats (n = 8/sex/group, Charles River Laboratories,
Portage, MI)  were administered S2227 as a suspension in 1% MC  by
oral gavage at dose levels of 10, 30, or 100 mg/kg/day (dose volume
of 10 mL/kg). One additional group of eight animals/sex served as
the control and received only vehicle.
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Table 8
Summary of subchronic and developmental toxicity studies conducted on S2227.
Study Species/gender (N value) Dose Findings
28-Day dose range ﬁnding toxicity study Male & female Sprague-Dawley
rats
8 animals/sex/group
10, 30, 100 mg/kg/day
(oral gavage)
No test-article related ﬁndings;
NOEL = 100 mg/kg/day
90-Day subchronic toxicity study Male & female Sprague-Dawley
rats
Main study:
20 animals/sex/group
TK satellite group:
6 animals/sex/group
10, 30, 100 mg/kg/day
(oral gavage)
No test-article related ﬁndings;
NOEL = 100 mg/kg/day
Dose range ﬁnding developmental toxicity study Bred female Sprague-Dawley rats
8  animals/group
125, 250, 500, 1000 mg/kg/day
(oral gavage)
No maternal toxicity up to
1000 mg/kg/day; slight effect on
intrauterine growth (fetal weight)
at 1000 mg/kg/day
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aDeﬁnitive developmental toxicity study Bred female Sprague-Dawl
25 animals/group
Survival, clinical observations, body weight, food consump-
ion, clinical chemistry, ophthalmic examinations, organ weights,
nd macroscopic evaluations of all animals were used to assess
otential toxicity. The livers and gastrointestinal tissues (stomach,
uodenum, jejunum, and ileum) were examined microscopically
or animals in the 0 and 100 mg/kg/day dose groups.
Once daily oral administration of S2227 for 28 days was  well
olerated in rats at dose levels up to 100 mg/kg/day, the highest
ose tested. There was no test article-related mortality observed
nd all animals survived until scheduled euthanasia. There were
o test article-related clinical signs or changes in mean body
eight, body weight gain, food consumption, ophthalmic examina-
ions, hematology parameters, coagulation parameters, red blood
ell morphology, clinical chemistry parameters, macroscopic or
icroscopic urinalysis data, or urine chemistry parameters during
his study. There were no test article-related gross observations,
hanges in absolute or relative organ weights, or microscopic ﬁnd-
ngs observed in the limited protocol-required tissues examined at
tudy termination. Based on these results, the no-observed-effect
evel (NOEL) was  considered to be ≥100 mg/kg/day.
.1.2. 90-Day subchronic toxicity study
The purpose of these studies was to evaluate the potential sub-
hronic toxicity and toxicokinetic (TK) proﬁle of S2227, in rats
fter administration by oral gavage for 90 consecutive days. A sus-
ension of S2227 in 1% MC  was administered by oral gavage to
our groups of twenty male and twenty female Sprague-Dawley
Crl:CD®(SD)] rats (Charles River Laboratories, Portage, MI)  at dose
evels of 0 (control), 10, 30, or 100 mg/kg/day for 90 consecutive
ays. Additionally, one control group of three animals/sex and three
reated groups of six animals/sex/group served as TK animals and
eceived the vehicle or test article in the same manner as the main
tudy groups at respective dose levels of 0 (control), 10, 30, and
00 mg/kg/day.
Survival, clinical observations, body weight gain, food consump-
ion, hematology, clinical chemistry, urinalysis, organ weights,
acroscopic examination, and histopathologic evaluation of at
east 54 tissues (control and high dose animals only; see Sup-
lementary data for list of tissues examined histopathologically)
ere performed to assess potential toxicity. A functional observa-
ional battery (including, but not limited to, evaluation of activity,
rousal, autonomic and physical function, neuromuscular function,
alvation, and respiration) and opthalmoscopic examinations were
onducted pretest and again during 13th week of test article admin-
stration for all main study animals. Samples for hematology and
linical chemistry evaluations were collected from all main study
nimals during Week 1 and Week 6, and again prior to termination.s 125, 300, 1000 mg/kg/day
(oral gavage)
NOAEL for both maternal toxicity
and embryo/fetal
development = 1000 mg/kg/day
Urinalysis and samples for coagulation evaluations were collected
prior to termination only. Blood for TK analysis was collected on
days 1, 44 and 90 at pre-dose, 1, 3, 6, 12, and 24 h at alternating
time points from two cohorts of 3 animals/sex/group. Microscopic
examination of ﬁxed hematoxylin and eosin-stained parafﬁn sec-
tions were performed on sections of tissues from the control and
high-dose (100 mg/kg/day) groups.
Previous PK studies on the test article S2227 in rats have shown
that the amide bond of S2227 rapidly hydrolyzes in vivo to the
corresponding carboxylic acid M166 and secondary amine M179.
As a result, the plasma levels of S2227 are very low. In con-
trast, plasma levels of the carboxylic acid hydrolysis product M166
were quite high and increased in proportion to dose. Therefore,
for the TK analysis associated with this study, M166 was used as
a surrogate for demonstrating proof of exposure to S2227 using
a validated analytical procedure. All animals in the 10, 30, and
100 mg/kg dose groups were exposed to M166 on Days 1, 44, and
90 and were generally quantiﬁable until at least 12 h post-dose
(see Table 9). For the 100 mg/kg males, M166 was quantiﬁable
over the whole sampling interval (24 h). Time to maximum plasma
concentration (Tmax) was  reached at 1 or 3 h post-dose across
occasions. At the 100 mg/kg/day dose, Cmax of M166 ranged from
6790 to 7730 ng/mL (40.9–46.6 M)  in females, and from 5040
to 9290 ng/mL (30.4–56.0 M)  in males, throughout the duration
of the study. Maximum plasma concentration was followed by
a mono-exponential decline of M166 with half-lives (t1/2) rang-
ing between 1.43 and 4.41 h. Overall, AUClast increased in a less
than dose-proportional manner between 10 and 30 mg/kg/day, and
between 30 and 100 mg/kg/day. The exposure to M166 on Day 90
when compared to Day 1 was  similar for all female animals of all
dose levels with accumulation ratios (RAUC) ranging from 1.07 to
1.19. For male animals, M166 exposure on Day 90 decreased by
approximately half when compared to Day 1 and accumulation
ratios ranged from 0.413 to 0.701. A gender difference was observed
for AUClast values on Days 44 and 90 where higher systemic expo-
sure in females compared to males was observed, whereas on Day
1, exposure was  similar.
There were no test article-related deaths during the study.
All animals survived until scheduled euthanasia on Days 91–93.
There were no test article-related clinical signs observed during
the study. Labored breathing and abnormal breathing sounds were
observed only once (in a single animal) during the study (Day 63)
and were most likely related to inadvertent aspiration during the
gavage procedure; therefore, these ﬁndings were considered inci-
dental. No test article-related changes were observed in functional
observational battery or ophthalmic assessments in test article-
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Table  9
Toxicokinetics of M166 in male and female Sprague-Dawley rats treated with S2227 by oral gavage for 90 days.
Day Dose (mg/kg) Sex Cmax (ng/mL) Tmax (h) t1/2 (h) AUC0–24h (ng·h/mL) AUC0–24h/dose (ng·h/mL/mg/kg) RAUCa
1 10 M 1820 ± 494 3.0 1.63 9840 ± 1630 984 –
F  1740 ± 163 1.0 1.43 8040 ± 542 804 –
30  M 4400 ± 921 3.0 2.26 25200 ± 4630 841 –
F  4070 ± 922 3.0 2.47 22500 ± 3200 751 –
100  M 9290 ± 618 3.0 2.75 55000 ± 4490 550 –
F  7730 ± 2500 3.0 2.28 54500 ± 11 400 545 –
44 10  M 1250 ± 94.4 3.0 1.98 8220 ± 876 822 0.835
F  1910 ± 484 3.0 2.03 10200 ± 1600 1020 1.27
30  M 2970 ± 382 3.0 4.41 16200 ± 1270 540 0.642
F  4500 ± 845 3.0 2.23 24800 ± 4390 826 1.10
100  M 5040 ± 557 3.0 2.96 39300 ± 2490 393 0.716
F  6790 ± 1170 3.0 2.78 56100 ± 12 100 561 1.03
90 10  M 1180 ± 275 3.0 4.21 6900 ± 1010 690 0.701
F  1670 ± 226 1.0 2.79 8760 ± 929 876 1.09
30  M 2450 ± 274 1.0 3.80 10400 ± 1200 347 0.413
F  3890 ± 1350 3.0 2.43 26800 ± 5200 894 1.19
100  M 5140 ± 1260 3.0 3.71 31600 ± 5850 316 0.575
2 
t
s
a
i
s
o
u
s
m
d
a
c
d
N
c
t
S
s
6
6
S
c
w
C
f
5
t
c
o
c
p
d
a
v
a
p
e
wF  7210 ± 1820 3.0 3.3
a RAUC = Day 44 or 90 AUC0–24h/Day 1 AUC0–24h
reated animals compared to the controls or pretest values in this
tudy.
There were no test article-related changes observed in mean
bsolute body weights or body weight gain (see Figs. 9 and 10)
n the S2227-treated animals compared to the controls in this
tudy. There were no test article-related effects among hematol-
gy parameters, coagulation times, clinical chemistry analytes, or
rinalysis parameters in either sex at any dose level.
There were no test article-related organ weight, macro-
copic or microscopic changes noted at any dose level. All
acroscopic and microscopic observations were considered inci-
ental/spontaneous, of the nature commonly observed in this strain
nd age of rats, and/or were of similar incidence and severity in
ontrol and treated animals.
In conclusion, once daily oral administration of S2227 for 90
ays was well tolerated in rats at dose levels up to 100 mg/kg/day.
o test article-related mortality or evidence of any systemic toxi-
ity was observed and no target organs were identiﬁed. Based on
hese results, the NOEL was considered to be ≥100 mg/kg/day. See
upplementary data for summary of the 90-day subchronic toxicity
tudy data for S2227.
.2. Developmental toxicity studies
.2.1. Dose range-ﬁnding developmental toxicity study
The objective of the study was to determine dosage levels of
2227 to be evaluated in a deﬁnitive developmental toxicity study
onducted in rats. The test article, S2227, in the vehicle (1% MC)
as administered orally by gavage to 4 groups of 8 bred female
rl:CD(SD) rats (Charles River Laboratories, Raleigh, NC) once daily
rom gestation Days 6 through 20, with dosage levels of 125, 250,
00, or 1000 mg/kg/day (dose volume 10 mL/kg). A concurrent con-
rol group composed of 8 bred females received the vehicle on a
omparable regimen. The females were approximately 13 weeks
f age when paired for breeding. Positive evidence of mating was
onﬁrmed by the presence of a vaginal copulatory plug or the
resence of sperm in a vaginal lavage. The day on which evi-
ence of mating was identiﬁed was termed gestation Day 0. All
nimals were observed for mortality, moribundity, clinical obser-
ations, body weights, and food consumption. On gestation Day 21, laparohysterectomy was performed on each female. The uteri,
lacentae, and ovaries were examined, and the numbers of fetuses,
arly and late resorptions, total implantations, and corpora lutea
ere recorded. Gravid uterine weights were recorded, and net body58100 ± 9030 581 1.07
weights and net body weight changes were calculated. The fetuses
were weighed, sexed, and examined for external malformations
and developmental variations.
All females survived to the scheduled necropsy on gestation
Day 21. Limited occurrences of clear and/or red material around
the mouth were observed at 125, 250, 500, and 1000 mg/kg/day at
approximately 1 h following dose administration during the latter
portion of gestation (Days 17–20). In addition, increased occur-
rences of hair loss on various body surfaces were noted in the 500
and 1000 mg/kg/day groups at the daily examinations throughout
the treatment period.
Following the initiation of dose administration on gestation Day
6–7, lower mean body weight gains and corresponding reduced
mean food consumption were noted in the 500 and 1000 mg/kg/day
groups during gestation Days 6–9. Mean body weight gains and
food consumption in these groups were similar to the control
group during the remainder of gestation. The initial mean body
weight loss noted in the 500 and 1000 mg/kg/day groups resulted
in slightly lower mean body weight gains when the entire treat-
ment period (gestation Days 6–21) was evaluated, but was not
of sufﬁcient magnitude to affect mean body weights. Mean net
body weights, net body weight gains, and gravid uterine weights
in the 125, 250, 500, and 1000 mg/kg/day groups were similar to
that in the control group. At the scheduled necropsy on gestation
Day 21, no remarkable internal ﬁndings were observed at dosage
levels of 125, 250, 500, and 1000 mg/kg/day and all females were
determined to be gravid.
Mean combined fetal weight in the 1000 mg/kg/day group
(5.1 g) was 8.9% lower than the concurrent control group value
(5.6 g). Intrauterine growth in the 125, 250, and 500 mg/kg/day
groups and survival and external fetal morphology in the 125, 250,
500, and 1000 mg/kg/day groups were unaffected by test article
administration. Based on these results, dosage levels of 125, 300,
and 1000 mg/kg/day were selected for a deﬁnitive embryo/fetal
development study of S2227 administered orally by gavage to bred
Crl:CD(SD) rats.
6.2.2. Deﬁnitive developmental toxicity study
The objective of the study was  to determine the potential of
S2227 to induce developmental toxicity after maternal exposure
from implantation to one day prior to expected parturition, to char-
acterize maternal toxicity at the exposure levels tested, and to
determine a NOAEL for maternal and developmental toxicity. S2227
was administered orally by gavage (in vehicle 1% MC)  to 3 groups of
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5 bred female Crl:CD(SD) rats (Charles River Laboratories, Portage,
I)  once daily from gestation Days 6 through 20, at dosage levels
25, 300, or 1000 mg/kg/day. A concurrent control group composed
f 25 bred females received the vehicle on a comparable regimen.
he females were approximately 11 weeks of age when paired for
reeding. Positive evidence of mating was conﬁrmed by the pres-
nce of a vaginal copulatory plug or the presence of sperm in a
aginal lavage. The day on which evidence of mating was identi-
ed was termed gestation Day 0. All animals were observed for
ortality, moribundity, clinical observations, body weights, and
ood consumption. On gestation Day 21, a laparohysterectomy was
erformed on each female. The uteri, placentae, and ovaries were
xamined, and the numbers of fetuses, early and late resorptions,
otal implantations, and corpora lutea were recorded. Gravid uter-
ne weights were recorded, and net body weights and net body
eight changes were calculated. The fetuses were weighed, sexed,
nd examined for external, visceral, and skeletal malformations and
evelopmental variations.
All females survived to the scheduled necropsy on gestation Day
1. Non-adverse test article-related clinical ﬁndings in the 300 and
000 mg/kg/day groups included clear and/or red material around
he mouth and nose at approximately 1 h following dose admin-
stration in 11 and 15 females, respectively. These ﬁndings began
s early as gestation Day 12 with the majority occurring between
estation Days 17 and 20. These material ﬁndings were consid-
red test article-related, but non-adverse because they generally
id not persist to the daily examinations the following day. No test
rticle-related ﬁndings were noted at 1 h following dose adminis-
ration in the 125 mg/kg/day group. No test article-related clinical
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Fig. 10. Mean body weights of female Sprague-Dawley rats receiving S2227 for 13 wedy Day
ks (Days -7 to 85, n = 20/group; Days 91–92, n = 7/group; Day 93, n = 6/group).
ﬁndings were noted at the daily examinations for any of the test
article-treated groups.
Mean body weight loss and lower food consumption were noted
following the ﬁrst day of dose administration (gestation Day 6–7)
in the 1000 mg/kg/day group compared to the control group. This
weight loss was followed by a signiﬁcant mean body weight gain
on gestation Day 7–8 compared to the control group. Mean body
weight gains in the 1000 mg/kg/day group were similar to the con-
trol group during the remainder of the treatment period (gestation
Days 8–21). The effects on body weight change and/or food con-
sumption in the 1000 mg/kg/day group was transient and not of
sufﬁcient magnitude to affect mean body weights for the over-
all treatment period, and therefore, were not considered adverse.
Mean net body weights (Fig. 11), net body weight changes, and
gravid uterine weights in the 125, 300 and 1000 mg/kg/day groups
were unaffected by test article administration.
At the scheduled necropsy on gestation Day 21, no test article-
related internal ﬁndings were observed at dosage levels of 125,
300, and 1000 mg/kg/day. Macroscopic ﬁndings observed in the test
article-treated groups occurred infrequently, at similar frequencies
in the control group, and/or in a manner that was not dose-related.
One female in the 1000 mg/kg/day group was non-gravid.
Intrauterine growth and survival were unaffected by test article
administration at any dosage level. Parameters evaluated included
post-implantation loss, live litter size, mean fetal body weights,
and fetal sex ratios (see Table 10). Mean numbers of corpora lutea
and implantation sites and the mean litter proportions of pre-
implantation loss were similar across all groups. Differences from
the control group were slight and not statistically signiﬁcant.
50 70 90
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eks (Days -7 to 85, n = 20/group; Days 91–92, n = 7/group; Day 93, n = 6/group).
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Table 10
Developmental toxicity study of S2227 in rats: summary of fetal data.
Dose group (mg/kg/d) Fetuses Sex Viable fetuses Dead
fetuses
Resorptions Post-
implant.
Loss
Implant.
sites
Corpora Lutea Pre-
Implant.
loss
Fetal Wt.(g) No. of
gravid
females
M F Early Late
0 Total 183 197 380 0 17 0 17 397 415 18 NA 25
Mean 7.3 7.9 15.2 0.0 0.7 0.0 0.7 15.9 16.6 0.7 5.8
S.D.  2.27 2.09 2.20 0.00 0.80 0.00 0.80 2.07 2.40 0.94 0.27
S.E.  0.45 0.42 0.44 0.00 0.16 0.00 0.16 0.41 0.48 0.19 0.05
125 Total 192 168 360 0 20 0 20 380 433 53 NA 25
Mean 7.7 6.7 14.4 0.0 0.8 0.0 0.8 15.2 17.3 2.1 5.7
S.D.  2.98 2.72 4.36 0.00 1.00 0.00 1.00 3.84 3.76 3.05 0.25
S.E.  0.60 0.54 0.87 0.00 0.20 0.00 0.20 0.77 0.75 0.61 0.05
300 Total 176 185 361 0 24 2 26 387 422 35 NA 25
Mean 7.0 7.4 14.4 0.0 1.0 0.1 1.0 15.5 16.9 1.4 5.6
S.D.  2.11 2.53 2.53 0.00 1.02 0.28 1.06 2.47 2.54 1.53 0.29
S.E.  0.42 0.51 0.51 0.00 0.20 0.06 0.21 0.49 0.51 0.31 0.06
1000 Total 188 185 373 0 14 0 14 387 419 32 NA 24
Mean 7.8 7.7 15.5 0.0 0.6 0.0 0.6 16.1 17.5 1.3 5.7
S.D.  2.78 2.65 1.74 0.00 0.83 0.00 0.83 1.48 2.41 1.83 0.21
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A = not applicable
The numbers of fetuses (litters) available for morphological
valuation were 380(25), 360(24), 361(25), and 373(24) in the
ontrol, 125, 300, and 1000 mg/kg/day groups, respectively. Malfor-
ations were observed in 0(0), 2(2), 3(2), and 0(0) fetuses(litters)
n these same respective dose groups and were considered spon-
aneous in origin. In the 300 mg/kg/day group, a malformation of
nophthalmia (bilateral) was observed in one fetus. There was
o apparent skeletal origin for this ﬁnding. In the 125 mg/kg/day
roup, a malformation of cleft palate was observed in one fetus. The
forementioned ﬁndings at 125 and 300 mg/kg/day were not con-
idered test article-related because they occurred in single fetuses
n a manner that was not dose-related, and mean litter propor-
ions were within the laboratories historical control data ranges. No
ther external malformations were observed at any dosage level.
o external developmental variations were noted in this study.
There were no test article-related soft tissue malformations
r variations noted for fetuses at any dosage level. In the
00 mg/kg/day group, lobular dysgenesis of the lungs (one lobe
resent, bilateral) and right-sided aortic arch were observed in
ne fetus. A retroesophageal aortic arch was noted for another
etus in this same litter. No other soft tissue malformations were
bserved in the test article-treated groups. The soft tissue develop-.00 0.17 0.30 0.49 0.37 0.04
mental variation of renal papilla(e) not developed and/or distended
ureters was  noted in 13(3), 13(4), 4(2), and 26(5) fetuses(litters)
in the control, 125, 300, and 1000 mg/kg/day groups respectively.
The 125 and 1000 mg/kg/day mean litter proportion (3.7% and 6.7%
per litter, respectively) exceeded the maximum mean value in the
laboratory’s historical control data (3.5% per litter). However, this
common variation was  not considered test article-related because
it was not statistically signiﬁcantly different from the concurrent
control group, and only occurred in a limited number of litters.
Other soft tissue developmental variations observed in the test
article-treated groups consisted of a major blood vessel variation
(right carotid and right subclavian arteries arose independently
from the aortic arch) and hemorrhagic ring around the iris.
There were no test article-related skeletal malformations or
variations noted for fetuses at any dosage level. A vertebral anomaly
with or without associated rib anomaly was  noted for one fetus in
the 125 mg/kg/day group and one fetus in the 300 mg/kg/day group.
No skeletal malformations were noted in the 1000 mg/kg/day
group. Skeletal variations were observed with similar frequency
in all groups, including the control group, and consisted mainly
of 14th rudimentary rib(s) and 7th cervical rib(s). The aforemen-
tioned visceral and skeletal malformations and variations were not
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onsidered test article-related because they were noted in single
etuses, not in a dose-related manner, and/or the mean litter pro-
ortions were within the laboratory’s historical control data ranges.
 detailed summary of all of the external, visceral, and skeletal mal-
ormations and variations seen in this study can be found in the
upplemental data section.
Based on the lack of adverse maternal toxicity or effects on
ntrauterine growth and survival and fetal morphology at any
osage level, a dosage level of 1000 mg/kg/day (the highest dosage
evel evaluated) was considered to be the NOAEL for maternal toxi-
ity and embryo/fetal development when S2227 was  administered
rally by gavage to bred Crl:CD(SD) rats.
. Discussion
S2227 is a member of a novel series of substituted phenoxy-
cetylamide TRPM8 activators which differ from the currently
arketed p-menthane carboxamide cooling agents mainly by the
eplacement of the p-menthane-3-carboxylic acid moiety with a
henoxyacetic acid derivative. In CYP450 inhibition assays using
oth spectroﬂuorimetric substrates with recombinant enzymes
nd CYP-speciﬁc substrates with pooled human liver microsomes,
2227 exhibited signiﬁcant inhibition of CYP2C19 and CYP3A4
IC50’s = 1.3 M and 15 M,  respectively using pooled human liver
icrosomes). However, given the low anticipated use levels of
2227 [3] and its low systemic bioavailability after oral admin-
stration, this is not expected to interfere with normal metabolic
rocesses. Other cooling compounds such as FEMA 3455 and 4496
ave also shown signiﬁcant inhibition of CYP2C19 when proﬁled
gainst the same panel of CYP450 enzymes (74% and 84% inhibi-
ion, respectively at 10 M using spectroﬂuorimetric substrates;
rthur, unpublished results). No other signiﬁcant off-target activ-
ties were seen in any of the receptor proﬁling assays with 10 M
f S2227.
S2227 was rapidly converted to its component carboxylic acid
166 and secondary amine M179 on both intravenous and oral
dministration in mouse, rat, and dog. In contrast, the amide bond
f the p-menthane carboxamides FEMA 4309 and 4496 has been
hown to be resistant to hydrolysis in artiﬁcial pancreatic juice,
iver homogenate, and rat and human liver microsomes [7,8]. On
ral administration of S2227 to either mouse, rat, or dog, the expo-
ure (AUC) to the carboxylic acid hydrolysis product M166 was
igniﬁcantly higher than to either the parent amide S2227 or to
he secondary amine hydrolysis product M179. This appears to be
articularly true in the dog and in the mouse, where only very low
evels of M179 were seen in plasma. The observation that amine
179 is not produced in proportion to carboxylic acid M166 sug-
ests that either M179 is undergoing further metabolism, or that
he amine moiety of S2227 is being metabolized prior to cleavage of
he amide bond. However, the plasma half-life of M179 in the dog
s not signiﬁcantly different from that of M166 suggesting that the
atter may  be the case. This is further supported by the observation
hat oral administration of M179 hydrochloride salt to mice results
n signiﬁcantly higher exposure of M179 in plasma (158-fold) than
n equimolar dose of S2227, and also indicates that hydrolysis of
2227 is not occurring to a signiﬁcant extent in the intestinal lumen.
In a PK study on a closely related compound, 2-(4-
ethylphenoxy)-N-ethyl-N-(2-thienylmethyl) acetamide (S5031),
n rats equipped with jugular and hepatic vein catheters, there was
ar more intact S5031 relative to the hydrolysis products in the
ortal blood verses the jugular blood [AUC0–8h ratio (amide/acid):
V = 0.52; JV = 0.013; Chi, unpublished results]. This indicates that,
lthough some hydrolysis of the amide occurred on absorption,
he majority of the amide bond cleavage of S5031 occurred on
rst-pass through the liver. As also seen in the case of S2227, theReports 2 (2015) 1291–1309
secondary amine hydrolysis product was not present in propor-
tion to the acid in either the portal or jugular veins [S5031 AUC0–8h
ratio (acid/amine): PV = 13.3; JV = 23.0]. Taken together with the
results of the in vitro microsomal metabolism studies, these ﬁnd-
ings indicate that the amine moiety of S2227 is, at least to some
extent, undergoing oxidative metabolism in the liver (and possi-
bly the intestine) prior to cleavage of the amide bond on ﬁrst-pass
through the liver.
In addition to the carboxylic acid M166 and secondary amine
M179 amide bond hydrolysis products, seven Phase I and two  Phase
II metabolites of S2227 were observed in the rat plasma samples. A
third Phase II metabolite, glucuronide M519A, was only seen in dog
plasma. None of the microsomal metabolites involving oxidation of
the thiophene ring were seen in either the rat or dog plasma sam-
ples at any time point. Most of the remaining human microsomal
Phase I metabolites were present in both rat and dog plasma and
tended to be present in higher concentrations in the rat than in the
dog. Based both the pharmacokinetic and in vivo metabolism data
in both rat and dog, the rat was  viewed as a suitable species for the
evaluation of the in vivo toxicology of S2227.
Both S2227 and its secondary amine hydrolysis product M179
were evaluated for their genotoxic potential through a standard
battery of in vitro genotoxicity assays which included a bacte-
rial reverse mutation assay (S. typhimurium strains TA98, TA100,
TA1535, TA1537 and E. coli strain WP2  uvrA), and a chromosome
aberration test in HPBL. S2227 was  found to be neither mutagenic
or clastogenic in these in vitro genotoxicity assays. Although sec-
ondary amine M179 showed no evidence of mutagenicity in the
bacterial reverse mutation assays or clastogenicity in the chromo-
somal aberration assay in presence of metabolic activation, human
lymphocytes exposed to M179 in the absence of S9 showed a
signiﬁcant increase in cells with structural (but not numerical)
chromosomal aberrations (5.5–6.0%, p ≤ 0.01). This was  only seen
in the 4 h non-activated cultures and was  not seen in the 20 h cul-
tures in the absence of S9. p-Menthane carboxamides FEMA 4496,
4549, and 4681 have also been shown to be non-mutagenic in a
bacterial reverse mutation assay using the same tester strains at
concentrations up to 5000 g/plate with and without metabolic
activation [7,8]. FEMA 4309 was  found to be weakly positive to
TA1535 in the absence of metabolic activation, but was non-
mutagenic in the other tester strains and also in a L5178Y TK+/−
mouse lymphoma assay at concentrations up to 672.5 g/mL (-S9)
and 1008.75 g/mL (+S9) [7]. FEMA 4496 and 4549 were also found
to be non-clastogenic in a chromosomal aberration test in HPBL in
the presence and absence of metabolic activation at concentrations
up to 2984 g/mL and 300 g/mL, respectively [8].
Both S2227 and M179 hemisulfate salt were also evaluated in
an in vivo mouse micronucleus assay. Oral administration of S2227
(males and females: 2000 mg/kg) or M179 (males: 500 mg/kg;
females: 1000 mg/kg) to CD-1 mice for three consecutive days was
well tolerated and did not induce clastogenicity nor indicate inter-
actions with the mitotic spindle in bone marrow erythrocytes. No
appreciable reductions in the PCE/TE ratio in the test article groups
compared to the vehicle control group were observed indicating
neither compound induced bone marrow toxicity. FEMA 4549, the
only p-menthane carboxamide evaluated in the in vivo mouse bone
marrow micronucleus assay, also was  negative for clastogenicity at
oral doses (gavage) up to 2000 mg/kg [8].
Given the apparent positive results for M179 in the chromo-
somal aberration assay, the livers of the mice treated with M179
were also examined for evidence of DNA damage by single cell gel
electrophoresis (i.e., the alkaline comet assay) in the same animals
evaluated for induction of mnPCEs in bone marrow. Although M179
is produced in vivo from an oral dose of S2227 in mice, the exposure
to M179 after an oral dose its hydrochloride salt was signiﬁcantly
higher than seen with a molar equivalent dose of S2227 (158-
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old). Therefore, it was felt that an independent evaluation of the
n vivo genotoxicity potential of M179 was necessary. In the same
nimals assessed for micronuclei induction, M179 was  negative
non-DNA damaging) in the liver based on the results of the comet
ssays. Overall, the results of the genotoxicity studies conducted
n both S2227 and the p-menthane carboxamide cooling agents
ndicate no safety concern for these substances with respect to
enotoxicity.
The doses of S2227 selected for the 28 and 90 day toxicology
tudies were designed to provide a high margin of safety rather than
eﬁne a maximum tolerated dose (MTD) in rats. Applying a 1000-
old margin of exposure in extrapolating animal data to humans
o account for species differences in susceptibility, numerical dif-
erences in population ranges between the test animals and the
uman population, the greater variety of complicating disease pro-
esses in the human population, and the possibility of synergistic
ction among food additives, is believed to be an adequate margin
f safety for most substances proposed for use in food [19,6]. Based
n the anticipated annual volume of use (2000 kg), the per capita
ntake (“eaters only”) of S2227 for use as a ﬂavor ingredient was
alculated to be 290 g/person/day (5 g/kg bw/day, Cohen et al.,
015). Therefore, based on the low anticipated use level of S2227, a
o-observed-effect-level (NOEL) of 100 mg/kg/day in a sub-chronic
oxicology study would provide over a 20,000-fold margin of safety.
For the TK analysis associated with the 90-day subchronic toxi-
ology study of S2227, carboxylic acid M166 was  used as a surrogate
or demonstrating proof of exposure to S2227. While the exposure
o M166 on Day 90 when compared to Day 1 was  similar for all
emale animals at all dose levels, M166 exposure for the male ani-
als decreased by approximately half when compared to Day 1.
 gender difference was observed for AUClast values on Days 44
nd 90 where higher systemic exposure in females compared to
ales was observed, whereas on Day 1, exposure was similar. Taken
ogether, these results suggest that repeat dosing of S2227 may
e inducing the further metabolism of M166 in males, but not in
emale rats. In vivo metabolism studies in rats have shown that
166 can be further metabolized to alcohol/acid M182 and dicar-
oxylic acid M196. Gender-dependent metabolism of xenobiotics
nd sexual dimorphisms in response to inducing agents are well
nown phenomena in rats that has been attributed to differences in
he proﬁle of cytochrome P450 isozymes found in male and female
at liver [17,22].
In the 90-day subchronic toxicology study with S2227,
here were no test article-related effects among clinical signs,
ody weights, ophthalmic examinations, hematology parameters,
oagulation times, clinical chemistry parameters, or urinalysis
arameters, or in the functional observation battery in either sex
t any dose level. There were no test article-related organ weight,
acroscopic or microscopic changes in the tissues examined noted
t any dose level. The 90-day subchronic toxicity study established
 NOEL for S2227 of 100 mg/kg/day (the highest dose evaluated),
or both male and female Sprague-Dawley rats.
The in vivo toxicology of several of the p-menthane carboxam-
des has also been studied in rats. In both 28-day and 22-week
oxicology studies with FEMA 3455, administered by oral gavage
t doses up to 1000 mg/kg/day to Sprague-Dawley rats, mild liver
nd kidney toxicity was  observed at doses of 40 mg/kg/day and
bove. Likewise, in a 28-day toxicology study in beagle dogs at
00, 300, and 1000 mg/kg/day, administered by gelatin capsule,
ild liver toxicity was seen at all doses. Based on these studies,
he NOEL for FEMA 3455 was considered to be 8 mg/kg/day [9].
n a 90-day study with FEMA 4309 in Crl:CD (SD) rats (males and
emales) at doses of 25, 75, 225, and 675 mg/kg/day (oral gavage),
ematological changes (increase in monocytes, neutrophils, and
hite blood cells; decrease in hematocrit, hemoglobin, and red
lood cell count) seen at 225 and 675 mg/kg/day were dose-relatedReports 2 (2015) 1291–1309 1307
and considered adverse. At 675 mg/kg/day, increases in serum
creatinine, urea nitrogen, triglycerides, and total urine volume
were observed in both genders. Test-article related microscopic
ﬁndings where noted in the kidney (tubular degeneration and
dilation, interstitial ﬁbrosis, and tubular epithelium vacuolation)
and in the liver (periportal hepatocellular vacuolation and cen-
trilobular hepatocellular hypertrophy) in both males and females,
and in the hearts of females (cardiomyopathy) at 675 mg/kg/day.
The NOAEL for FEMA 4309 was considered to be 75 mg/kg/day
[7]. In a similar 90-day study in rats with FEMA 4496 at doses
of 100, 300, and 1000 mg/kg/day administered in diet, a test-
article related increase in methemoglobin was observed in the
females in the 1000 mg/kg/day group, and increased cholesterol
and potassium in males dosed at 300 and 1000 mg/kg/day. Sig-
niﬁcantly increased liver weight to body weight was observed in
both males and females dosed at 300 and 1000 mg/kg/day. There
were no histopathological substance-related changes in any tis-
sue. The NOAEL for this study was  considered to be 100 mg/kg/day
[8].
In a 28-day toxicology study in Sprague-Dawley rats with FEMA
4549 at doses of 10, 50, and 300 mg/kg/day administered in diet
(8 animals/sex/group), increases in albumin, globin, triglycerides,
cholesterol, T3, absolute and liver/body weight ratio were seen in
animals in the 300 mg/kg/day group. Follicular cell hypertrophy
of the thyroid gland was  observed in 7 males and 4 females in
the 300 mg/kg/day group, 2 males in the 50 mg/kg/day group, and
1 male each in the 10 and 0 mg/kg/day groups. The NOAEL was
considered to be 10 mg/kg/day. In a follow up 90-day study with
FEMA 4549 at 5, 20, and 50 mg/kg/day administered in diet (10 ani-
mals/sex/group), an increase in liver weights was  observed in the
high dose males with no histopathological correlate. Mild hepato-
cellular hypertrophy in females dosed at 20 and 50 mg/kg/day was
not considered to be adverse since there was no clinical chemistry
correlate. Dose-related increases in TSH, T4, and T3 were observed
in animals receiving 50 mg/kg/day. A dose-related follicular cell
hypertrophy was observed in the thyroid gland of males (all doses)
and females (5 and 50 mg/kg/day) treated with FEMA 4549. Given
that thyroid follicular hypertrophy can progress to neoplasia in rats,
the effects seen in the 20 and 50 mg/kg groups was considered to
be adverse. Thyroid gland effects were considered to be secondary
to hepatic microsomal enzyme induction. Induction of UDP  glu-
cocuronyltranferanse that conjugates T4 in liver would give rise to
compensatory increase in TSH in rat. In humans, T4 is metabolized
by sulfation, and therefore the observed effect in rat may  not be
relevant to humans. The NOAEL for this study was considered to
be 5 mg/kg/day [8]. With the exception of FEMA 4496, the NOAEL
for these 28- and 90-day toxicology studies of the p-menthane car-
boxamides in rats was below the 100 mg/kg/day NOEL observed
in the case of the 90-day study of phenoxyacetamide S2227 in
Sprague-Dawley rats. In the case of the p-menthane carboxam-
ides, target organs of toxicity included the liver, kidney, and thyroid
gland. There were no signs of toxicity in any of these organs in the
90-day study of S2227 in rats at doses up to 100 mg/kg/day (high-
est dose tested). According to the maximized survey-derived daily
intake (MSDI) approach, the margin of safety for the p-menthane
carboxamide based on the estimated daily per capita intake of
these substances in Europe was viewed to be adequate and they
are not anticipated to pose a safety concern when used as ﬂavor-
ing substances at the estimated levels of intake [8]. Although an
estimate of daily per capita intake of S2227 is not currently avail-
able, based on its approved use levels in various products [3] and
its higher NOEL in the 90-day toxicology study in rats, S2227 is
also believed not to pose a safety hazard when used as a ﬂavoring
substance.
In the developmental toxicity study of S2227, there were no
test article-related clinical or macroscopic ﬁndings were noted at
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ny dosage level. Mean maternal body weights, body weight gains,
ravid uterine weights, and food consumption were unaffected
y test article administration at all dosage levels. No test article-
elated ﬁndings were noted on intrauterine growth and survival
nd fetal morphology at any dosage level. Non-adverse test article-
elated clinical ﬁndings in the 300 and 1000 mg/kg/day groups
ncluded clear and/or red material around the mouth and nose at
pproximately 1 h following dose administration. These ﬁndings
ere considered test article-related, but non-adverse because they
enerally did not persist to the daily examinations the following
ay.
There were no test article-related external malformations, soft
issue, or skeletal malformations noted for fetuses at any dosage
evel. In the 300 mg/kg/day group, a malformation of anophthalmia
as observed in one fetus and in the 125 mg/kg/day group, a mal-
ormation of cleft palate was observed in one fetus. All of the
alformations observed in the study were considered to be spon-
aneous in origin and not test article-related. Based on the lack
f adverse maternal toxicity or effects on intrauterine growth and
urvival and fetal morphology at any dosage level, a dosage level
f 1000 mg/kg/day (the highest dosage level evaluated) was con-
idered to be the NOAEL for S2227 for both maternal toxicity and
mbryo/fetal development. No developmental or reproductive tox-
city studies have been reported for cooling compounds in the
-menthane carboxamide series.
. Conclusions
S2227 demonstrated a lack of genotoxicity with or without
etabolic activation in vitro at concentrations that greatly exceed
hose observed in rat plasma following oral administration of S2227
t doses up 100 mg/kg. Although the corresponding secondary
mine hydrolysis product M179 did show evidence of clastogenic-
ty in an in vitro chromosome aberration assay, both S2227 and
179 demonstrated a lack of genotoxicity in mice at oral doses
f 2000 mg/kg (male and female) and 500 (male)/1000 (female)
g/kg, respectively. S2227 had a NOAEL of 1000 mg/kg/day for
oth maternal toxicity and embryo/fetal development in rats. The
esults of a 90-day subchronic toxicity study established a NOEL for
2227 of 100 mg/kg/day (the highest dose evaluated), for male and
emale rats. Assuming that the systemic exposure of S2227 after
ral administration to humans is comparable to that observed at an
quivalent dose in the rat, these NOEL/NOAELs are several orders of
agnitude higher than the anticipated human exposure for S2227
nder the conditions of intended use [3].
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